Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 7/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.73 |
| ▸ | MAPT | P10636 | 7/20 | 0.73 |
| ▸ | MAOA | P21397 | 6/20 | 0.73 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.73 |
| ▸ | HPGD | P15428 | 5/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.73 |
| ▸ | BCL2 | P10415 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | RECQL | P46063 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | APEX1 | P27695 | 2/20 | 0.73 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.73 |
| ▸ | DAPK1 | P53355 | 2/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507679 | 0.91 | TTR (1.00) | TTRMEN1KMT2AMAPTMAOA | |
| SCHEMBL30695846 | 0.91 | TTR (1.00) | TTRMEN1KMT2AMAPTMAOA | |
| SCHEMBL30695849 | 0.91 | TTR (1.00) | TTRMEN1KMT2AMAPTMAOA | |
| SCHEMBL1495097 | 0.91 | TTR (1.00) | TTRMEN1KMT2AMAPTMAOA | |
| Anthraflavicacid SCHEMBL28102629 | 0.91 | MAOA (0.70) | TTRMEN1KMT2AMAPTMAOA | |
| Quinalizarin SCHEMBL9308575 | 0.86 | MAOA (0.80) | TTRMEN1KMT2AMAPTMAOA | |
| Athraquinones A SCHEMBL18614 | 0.85 | MAPT (1.00) | TTRMEN1KMT2AMAPTMAOA | |
| Athraquinones A SCHEMBL21114402 | 0.85 | MAPT (1.00) | TTRMEN1KMT2AMAPTMAOA | |
| Athraquinones A SCHEMBL4972786 | 0.85 | MAPT (1.00) | TTRMEN1KMT2AMAPTMAOA | |
| Athraquinones A SCHEMBL29373337 | 0.85 | MAPT (1.00) | TTRMEN1KMT2AMAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019032-A1 | Treatment of macular edema | TECHNOLAS PERFECT VISION GMBH (DE) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019032-A1 | Treatment of macular edema | VEGFA, PPOX, FLT4 | TTR 293/4885MEN1 3975/4885KMT2A 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.